Results 251 to 260 of about 7,263 (276)

Palonosetron (Helsinn).

Current opinion in investigational drugs (London, England : 2000), 2003
Palonosetron, a selective 5-HT3 receptor antagonist, is being developed by Helsinn for the potential treatment of chemotherapy-induced nausea and vomiting. By 1999, it was in phase III trials, and as of May 2002, an NDA filing was scheduled for the third quarter of 2002.
openaire   +1 more source

Palonosetron Hydrochloride

2022
Michelle C. Simpson, Eric G. Schaefer
openaire   +2 more sources

Palonosetron Hydrochloride

2021
  +4 more sources

Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis

Supportive Care in Cancer, 2023
Atsushi Yamaguchi, Y. Saito, Y. Takekuma, M. Sugawara   +3 more
semanticscholar   +1 more source

Palonosetron

Reactions Weekly, 2016
openaire   +2 more sources

Vacuum compression-molded polyvinyl alcohol microneedles for sustained three-day transdermal delivery of palonosetron hydrochloride.

Drug Delivery and Translational Research
Meheli Ghosh, Sharvari M. Kshirsagar, Thomas Kipping, Ajay K. Banga   +3 more
semanticscholar   +1 more source

Palonosetron

Reactions Weekly, 2017
openaire   +2 more sources

Palonosetron

Reactions Weekly, 2011
openaire   +1 more source

Palonosetron

2018
openaire   +2 more sources

Palonosetron

Reactions Weekly, 2010
openaire   +1 more source